Develops proprietary small-molecule drug candidates for potential treatments of Alzheimer’s disease, dry age-related macular degeneration and epidermolysis bullosa.
10-K for FY2026, filed Sep 9, 2026We are a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential…View ↗
We have sought to focus on the research and development of preferential signaling ligands of CB1 and CB2, and have produced a library of…View ↗
Our INM-901 is a proprietary small molecule, disease modifying drug candidate being developed as a potential treatment for Alzheimer’s…View ↗
Outcomes from our ocular research, based on the proprietary small molecule INM-089, indicate potentially promising neuroprotective effects…View ↗
We have completed a Phase 2 clinical trial of INM-755 (cannabinol) cream studying its safety and efficacy in treating symptoms related to…View ↗
$4.9M
10-K for FY2025, filed Sep 23, 2025
$4.9M ↗8-K, filed Nov 10, 2026
Item 2.01 Completion of Acquisition or Disposition of Assets.View ↗
Loading...